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Protein sumoylation by small ubiquitin-like modifier
(SUMO) proteins is an important post-translational reg-
ulatory modification. A role in the control of chromo-
some dynamics was first suggested when SUMO was
identified as high-copy suppressor of the centromere
protein CENP-C mutants. CENP-C itself contains a con-
sensus sumoylation sequence motif that partially over-
laps with its DNA binding and centromere localization
domain. To ascertain whether CENP-C can be sumoy-
lated, tandem mass spectrometry (MS) based strategy
was developed for high sensitivity identification and
sequencing of sumoylated isopeptides present among
in-gel-digested tryptic peptides of SDS-PAGE fraction-
ated target proteins. Without a predisposition to search-
ing for the expected isopeptides based on calculated
molecular mass and relying instead on the characteris-
tic MS/MS fragmentation pattern to identify sumolyla-
tion, we demonstrate that several other lysine residues
located not within the perfect consensus sumoylation
motif KXE/D, where  represents a large hydrophobic
amino acid, and X represnts any amino acid, can be
sumolylated with a reconstituted in vitro system con-
taining only the SUMO proteins, E1-activating enzyme
and E2-conjugating enzyme (Ubc9). In all cases, target
sites that can be sumoylated by SUMO-2 were shown to
be equally susceptible to SUMO-1 attachments which
include specific sites on SUMO-2 itself, Ubc9, and the
recombinant CENP-C fragments. Two non-consensus
sites on one of the CENP-C fragments were found to be
sumoylated in addition to the predicted site on the other
fragment. The developed methodologies should facili-
tate future studies in delineating the dynamics and sub-
strate specificities of SUMO-1/2/3 modifications and the
respective roles of E3 ligases in the process.
Protein modification by covalent attachment of SUMO1
(small ubiquitin-like modifier) proteins is emerging as an im-
portant regulatory mechanism in a diverse range of cellular
processes (1, 2). Through a three-step enzymatic pathway anal-
ogous to ubiquitylation, sumoylation is initiated by ATP-de-
pendent formation of a thioester bond between the C-terminal
glycine of a SUMO protein and a catalytic cysteine of the
SUMO-specific E1-activating enzyme, known as SAE1/SAE2
and Uba2p/Aos1p for human and yeast, respectively. The acti-
vated SUMO protein is then trans-esterified from the E1 en-
zyme to the catalytic cysteine of an E2-conjugating enzyme,
Ubc9, which in turn catalyzes the formation of an isopeptide
bond between the C-terminal glycine of SUMO and the -amino
group of lysine residue in the substrate proteins. Ubc9 was
reported to recognize and bind directly to a consensus sumoy-
lation motif KXE/D, where  represents a large hydrophobic
amino acid L, I, V, or F, and X represents any amino acid (3–5).
Although sumoylation can be accomplished in vitro without an
E3-like enzyme, several E3 ligases, e.g. PIAS, RanBP2, and
PC2, have been identified which may aid Ubc9 in substrate
selection and ligation efficiency in vivo (2, 6).
Unlike yeast and other invertebrates, which contain only a
single SUMO gene, vertebrates carry three. Human SUMO-1
protein exhibits 44% sequence identity with human SUMO-2
and SUMO-3 proteins, while SUMO-2 and SUMO-3 proteins
share 86% sequence identity. All SUMO proteins from yeast to
human share the conserved ubiquitin domain and the C-termi-
nal diglycine cleavage/attachment site (3, 7). The most promi-
nent difference between the SUMO proteins and ubiquitin is
the presence of a highly variable N-terminal extension in all
SUMO proteins, which is rich in charged amino acids, glycines,
and prolines. This extension varies from 16 to 23 amino acids
and is reasonably well conserved within, but not between,
different SUMO-1/2/3 proteins. At present, human SUMO-1
and SUMO-2/3 are thought to be functionally non-overlapping
and respond differently to stress signaling (2). Although all
three SUMO isoforms utilize the same E1-activating and E2-
conjugating enzymes, the molecular basis for their substrates
preference and the additional recruitment of E3 ligases, espe-
cially in relation to the selective use of sumoylation sites con-
forming and not conforming to the minimal consensus motif,
remain unclear. SUMO-2/3, like yeast SUMO (Smt3), but not
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SUMO-1, contain a consensus KXE sumoylation site in their
N-terminal extension. Accordingly, oligomerization of SUMO-
2/3 or Smt3 chains can be demonstrated in vivo and effected
with the reconstituted in vitro sumoylation system in the ab-
sence of E3 (8, 9). In contrast, formation of SUMO-1 chains
with as yet unknown linkage apparently can only be demon-
strated in the presence of an E3 ligase activity (10).
Sumoylation is a dynamic, reversible process, and often only
little or no modified protein can be detected under physiological
conditions (1). It should be noted that direct biochemical evi-
dence for the implicated isopeptide or the sumoylation site has
been generally lacking for most reported sumoylation cases due
to its low abundance. To date, only a handful of isopeptides
have been physically defined by mass spectrometry (MS) anal-
ysis (8, 9, 11, 12). The isopeptide formation and hence the
sumoylation site were directly inferred from the molecular
mass detected but in general not further verified by MS/MS
sequencing analysis. This approach is problematic in view of
the increasing probability in finding a non-consensus sumoy-
lation site nor can it distinguish the exact sumoylated lysine
residue in the event that the implicated endoproteinase-di-
gested peptide carries more than one lysine residues. To better
define the sumoylation site specificity and to delineate the
respective roles of SUMO-1 versus SUMO-2/3, a high sensitiv-
ity MS/MS sequencing strategy for unambiguous identification
of the isopeptide and sumoylation site is critically needed. By
adopting an in vitro sumoylation system with defined compo-
nents, we have thus undertaken to first develop the enabling
analytical techniques while gearing toward addressing the role
of sumoylation in regulating chromosome dynamics.
The centromere is a highly ordered structure of the eukary-
otic chromosomes which provides the site for microtubule (spin-
dle) attachment during cell division (13). The first implication
of sumoylation in centromere functions came from the original
isolation of the yeast SUMO (Smt3) as a high copy suppressor
of a mutation in the Mif2 gene, the yeast homologue of the gene
for mammalian centromere protein CENP-C (14). CENP-C is
an essential component of the kinetochore inner plate, which
contributes to the formation of functional centromeres for cor-
rect chromosome segregation. Temperature-sensitive CENP-C
mutants in vertebrate cells could likewise be suppressed by
overexpression of SUMO-1 (15). Despite several studies, which
demonstrated the localization of SUMO at or adjacent to the
kinetochore and how sumoylation may affect centromeric chro-
mosome cohesion (reviewed in Refs. 1 and 2), the mechanistic
details remain largely unknown nor is it clear whether critical
centromeric proteins like CENP-C are themselves sumoylated.
Molecular dissection of CENP-C revealed that the protein is
composed of several functional domains (16–21) including a
specific region of 12 amino acids at aa 522–533 that could
confer DNA binding as well as centromere targeting functions
(Fig. 1). Notably, its partial overlapping with a sumoylation
consensus sequence of VKSE at aa 533–536 raises an intrigu-
ing possibility that regulated sumoylation of CENP-C may
affect its functions.
Using the methodologies developed, which were first vali-
dated against SUMO-2/SUMO-2 and SUMO-2/Ubc9 conjuga-
tion, we report here that a C28 fragment of CENP-C encoding
aa 432–683 (Fig. 1), which includes the consensus sumoylation
site, DNA binding and centromere localization regions, and two
nuclear localization signals, could be in vitro sumoylated by
both SUMO-1 and SUMO-2 at the expected site in the absence
of any E3 ligases. In addition, another C10 fragment of
CENP-C encoding aa 678–764, which comprises a Mif2 homol-
ogy block at aa 737–759, could also be sumoylated in vitro by
both SUMO-1 and SUMO-2 at two distinct sites, neither of
which corresponds to the consensus sequence motif. We further
demonstrate that SUMO-1 could be attached to SUMO-2 and
the characteristic MS/MS fragmentation pattern associated
with SUMO-2 isopeptides could be utilized as an effective fin-
gerprint in identifying sumoylation site at high sensitivity.
EXPERIMENTAL PROCEDURES
cDNA Cloning, Protein Expression, and Purification—The C28 cDNA
encoding aa 432–683 of human CENP-C was amplified by reverse
transcriptase-PCR using poly(A)-containing RNAs from HeLa cells, as
well as primers of 5-CGGATCCAGAACACTTGATGTGGGAC-3 and
5-GTGCTCCAGTTCCTCTAAAACTGAAGT-3, and then cloned into
the BamHI-XhoI sites of bacterial expression vector pET-21b (His-tag
at the C terminus). The C10 cDNA encoding aa 678–764 of human
CENP-C was also amplified using primers of 5-CGGATCCCACTTCA-
GTTTTAGAGGAA-3 and 5-GTGCTCCAGTCCTGATGGCCTTCCTT-
GATA-3 and then cloned into the BamHI-XhoI sites of pET-21b. The
human cDNA encoding the active form (exposing diglycine motif) of
SUMO-1GG was obtained by PCR from the FLAG-SUMO-1 cDNA de-
scribed previously (22), and the cDNA encoding the active form of
FIG. 1. Partial amino acid sequences of human centromere protein CENP-C. Both C28 (aa 432–683) and C10 (aa 678–764) fragments
used in this study were constructed with the leader sequence MASMTGGQQMGADP and His-tag sequence LEHHHHHH as indicated, which were
subsequently cleaved off prior to in vitro sumoylation. Two distinct regions have been identified for centromere targeting, i.e. a central region
around aa 522–534 (underlined) (18, 20) and another region at the C terminus (aa 690–943) (17, 20), which includes the Mif2 homology domain
(aa 737–763, underlined) (14, 16). The implicated DNA-binding domains of CENP-C within the sequence shown include aa 330–551 (19), aa
433–520 (19), and aa 426–537 and 638–934 (21). The sumoylation sites identified in this study are Lys534 located within the consensus site VKSE
(aa 533–536), and the non-consensus sites at Lys721 and Lys746, as circled.
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SUMO-2GG was obtained by PCR from the hSMT3 cDNA reported
previously (23). Both SUMO-1GG and SUMO-2GG cDNAs were subse-
quently cloned into pET-32 Xa (both His-tag and S-tag at the N termi-
nus). The human Ubc9 cDNA was amplified by reverse transcriptase-
PCR using poly(A)-containing RNAs from HeLa cells and then cloned
into pET-21b and pET-32 Xa. The Escherichia coli BL21 strain was
used as host cells for protein expression. His-tag proteins were purified
using nickel-nitrilotriacetic acid-agarose column (Qiagen). The purified
proteins from pET-32 Xa were cleaved with Factor Xa to remove both
His-tag and S-tag.
In Vitro Sumoylation Assay—The in vitro sumoylation system em-
ployed in this investigation contains E1 enzyme (159 ng of SAE1/SAE2,
LAE Biotechnology, Taichung, Taiwan), E2 enzyme (2 g Ubc9),
SUMO-1GG or SUMO-2GG protein (5 g), and C28-His or C10-His
protein substrate (5 g) in sumoylation buffer (2 l of 500 mM Tris, pH
7.5, 1 l of 100 mM MgCl2, 1 l of 100 mM ATP, 0.5 l of 40 mM
dithiothreitol, an ATP-regenerating system, including 0.5 l of 400 mM
creatine phosphate, 0.5 l of 140 units/ml creatine kinase, 0.5 l of 24
units/ml inorganic pyrophosphatase). The sumoylation reactions were
incubated at 37 °C for 3 h. After termination with SDS buffer contain-
ing 1 mM dithiothreitol, reaction products were separated on 12% SDS-
PAGE, and the gels were stained with Coomassie Blue.
Identification of Sumoylation Sites by Tandem Mass Spectrometry
Analyses—Following SDS-PAGE, Coomassie Blue-stained protein
bands were excised from gels, reduced and alkylated with iodoacet-
amide, and in-gel-digested with sequencing grade, modified trypsin
(Promega, Madison, WI). Peptides were extracted and subjected first to
nanoLC-nanoESI-MS/MS analysis for protein identification as de-
scribed previously (24). Subsequently, MALDI-MS detection and
MS/MS sequencing of isopeptides in reflectron mode were performed on
an Applied Biosystems 4700 Proteomics Analyzer mass spectrometer
(Applied Biosystems, Framingham, MA) equipped with an Nd:YAG
laser (355 nm wavelength,500-ps pulse, and 200 Hz repetition rate in
both MS and MS/MS modes). 1000 and 10,000 shots were accumulated
in positive ion mode MS and MS/MS modes, respectively. The tryptic
digested peptide samples were dissolved in 50% acetonitrile with 0.1%
formic acids and premixed with a 5 mg/ml matrix solution of -cyano-
4-hydroxycinnamic acid in 70% acetonitrile with 0.1% formic acid for
spotting onto target plate. For collision-induced dissociation (CID)
MS/MS operation, the indicated collision cell pressure was increased
from 3.0  108 torr (no collision gas) to 5.0  107 torr, with the
potential difference between the source acceleration voltage and the
collision cell set at 1 kV. The resolution of timed ion selector for pre-
cursor ion was set at 100, which would allow in a mass window of about
50 Da for precursors at m/z 5000. Both MS and MS/MS data were
acquired using the instrument default calibration. At a resolution above
10,000 in MS mode, accurate mass measurement (50 ppm) of the
monoisotopic isopeptide signals is possible when further adjusted
against an internal reference peak at m/z 5557.8 derived from autolytic
cleavage of the modified trypsin.
RESULTS
Sumoylation of SUMO-2 and Ubc9—The in vitro sumoyla-
tion system employed in this investigation contained E1
(SAE1/SAE2)-activating enzyme, E2 (Ubc9)-conjugating en-
zyme, the active SUMO proteins (SUMO-1GG or SUMO-2GG),
with and without the centromere proteins (C28-His or C10-
His), and an ATP-generating system, including creatine ki-
nase. To better define the sumoylation reaction products as
visualized by SDS-PAGE analysis, reactions of the active
SUMO proteins with the E1/E2 enzymes were first investi-
gated prior to the addition of the substrate proteins. Fig. 2
shows that in the absence of E1 enzyme, no reaction product
could be detected (lanes 2 and 4), but one (lane 1) and two (lane
3) additional protein bands were clearly visible when E1 en-
zyme was added to the SUMO-1GG/E2 and SUMO-2GG/E2
reaction mixtures, respectively. By LC-ESI-MS/MS analysis of
the respective in-gel tryptic digests, bands 2 and 3 were found
to contain peptides derived from SUMO-1 and SUMO-2, re-
spectively, in addition to those from Ubc9 (data not shown).
Band 1 on the other hand only afforded peptides matching to
SUMO-2. Since the tagged SUMO proteins and Ubc9 alone ran
as protein bands close to 20 kDa (data not shown), the results
indicated that the SUMO proteins can be stably conjugated to
Ubc9 and ran as bands 2 and 3 and that only SUMO-2, but not
SUMO-1, can itself be sumoylated to give a higher molecular
weight product (band 1).
MS/MS Characteristics of SUMO-2-conjugated Isopeptides—
The monoisotopic mass of the SUMO-2-conjugated SUMO-2
isopeptide, in which the Gly93 of C-terminal tryptic peptide of
aa 62–93 from one SUMO-2 was conjugated to the sumoylation
site at Lys11 within the tryptic peptide of aa 8–21 from another
SUMO-2, was calculated to be 5159.34. By nanoESI-MS anal-
ysis on a quadrupole/time-of-flight instrument of sufficiently
high mass accuracy and resolution, a pair of well resolved,
quadruply charged isotopic signal clusters could be detected
with the respective monoisotopic molecular ions [M4H]4
occurring at m/z 1290.848 and 1294.847 (Fig. 3A, inset). The
former corresponds exactly (within 10 ppm) to the expected
isopeptide, while the latter at 16 mass units higher most likely
was derived from the same peptide but containing an oxidized
Met78 residue. The relative ratio of these two peaks varied from
batch to batch, implying different degree of induced oxidation
during sample preparation. To confirm the isopeptide linkage
assignment predicted by previous MALDI-TOF MS study (8),
the isopeptides detected here as singly charged [MH] mo-
lecular ions on a MALDI-TOF/TOF instrument were selected
as precursors for MALDI CID-MS/MS analysis (Fig. 3). Two
well known fragmentation characteristics facilitated the spec-
tral assignment. First, peptide fragmentation by MALDI-
MS/MS is often dominated by facile cleavages at C terminus of
an Asp residue (25). For tryptic peptides where the positive
charge tends to be localized to C-terminal Lys or Arg residue,
the MS/MS spectra will be dominated by a series of y ions, the
most abundant of which are derived from cleavages at Asp. In
the case of the SUMO-2 conjugated SUMO-2 isopeptide carry-
ing an oxidized Met (m/z 5180.6, Fig. 3A), the major ions at m/z
624.5 (y5), 2456.5 (y22), 2785.7 (y25), 3029.7 (y27), 4060.1 (y36),
and 4915.3 (y44) effectively and unambiguously confirmed the
peptide sequence. Other y ions, y5–y10, followed by the appar-
ent absence of y11–y13 and the reappearance of the y ion series
at y14 clearly define the SUMO-2 sumoylation site at Lys
11.
FIG. 2. SDS-PAGE analysis of sumoylation reaction products.
The in vitro sumoylation reactions contained the E2 (Ubc9) and SUMO-
1GG/2GG with and without the E1 enzyme, as well as creatine kinase
(CK). The gel was stained with Coomassie Blue for visualization of the
protein bands.
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Second, consistent with the presence of an oxidized Met resi-
due, the major fragment ions y36 and y44 and the molecular ion
that contains the oxidized Met were accompanied by facile
neutral loss of HSOCH3 (64 mass units) (26, 27), giving rise to
ions at m/z 3996.0, 4951.3, and 5116.9, respectively. These
neutral losses were not observed in the MS/MS spectra of
isopeptides with non-oxidized Met, e.g. that of the monoisotopic
[MH] molecular ion signal at m/z 5164.3 (data not shown).
FIG. 3. MALDI-MS/MS spectra of the SUMO-2-conjugated SUMO-2 isopeptides carrying an oxidized Met78 residue (A) or a trypsin
missed cleavage site at Arg61 (B). In A, the majority of the fragment ions could be assigned to the y ion series as annotated, which were
commonly accompanied by neutral loss of H2O (18 mass units) giving rise to pairs of signals. Ions that carry the oxidized Met also afforded neutral
loss of HSOCH3 (64 mass units). The quadruply charged molecular ion signals corresponding to the isopeptides containing a non-oxidized and
oxidized Met as detected by nanoESI-MS analysis are shown as the inset in A. The spectrum in B is normalized to the intensity of the b12 ion signal,
but only the portion below 50% intensity is shown. Localization of an Arg residue near the N terminus contributed to the predominance of the b
ion series except for a couple of y ions as annotated. Neutral loss of H2O (18 mass units) is also evident for the b21, b23, and b26 ions. The labeled
m/z values for this and other mass spectra figures mostly correspond to monoisotopic accurate masses as originally annotated by the instrument
except for signals at above m/z 3500, especially those of relatively weak intensity, which may not afford full isotopic resolution and may thus be
labeled according to the detected peak top, usually at several mass units higher than the theoretical monoisotopic masses.
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It is important to note that, depending on the substrate
proteins, the molecular weight of the SUMO-2-conjugated
isopeptide will naturally be different. However, the tryptic
fragment corresponding to the C-terminal peptide of SUMO-2
will remain the same. The four Asp residues, namely Asp71,
Asp80, Asp82, and Asp85, will always induce four major frag-
ment ions due to cleavage at their C termini with mass inter-
vals corresponding to 1014 (TPAQLEMED) or 1030
(TPAQLEMoxED), 244 (ED), and 329 (TID) mass units. Detec-
tion of this characteristic MALDI-MS/MS pattern is thus a first
indication that the parent ion signal is most probably a SUMO-
2-sumoylated isopeptide. As reported by others (8), there is a
tendency of missed cleavage by trypsin at the Arg61 located
immediately upstream of the 62–93 C-terminal peptide. As a
consequence of the additional two residues Phe60-Arg61 at the
N terminus, strong fragment ion signals corresponding to the b
ion series could be found to dominate the MS/MS spectrum in
place of the y ions, a phenomenon best rationalized as charge
localization at the N-terminal Arg in preference to the C-ter-
minal Lys. Consequently, the mass intervals of 1014/244/329
are now defined by the b ions, namely b12 (m/z 1420.6), b21 (m/z
2435.0), b23 (m/z 2679.0), and b26 (m/z 3008.2) ions for all
SUMO-2-conjugated isopeptides carrying the missed cleavage
which, together with the prominent b4 ion at m/z 566.3, consti-
FIG. 4. MALDI MS/MS spectra of the SUMO-2-conjugated Ubc9 isopeptide (A) and that with additional N-terminal FR due to
trypsin-missed cleavage at Arg61 (B). The spectrum in B is normalized to the intensity of the b12 ion signal, but only the portion below 50%
intensity is shown. The detected y ion series in A and the b ion series in B are analogous to those of SUMO-2-conjugated SUMO-2 isopeptides (Fig.
2). Oxidized Met was indicated by facile loss of 64 mass units. The characteristic mass intervals of 1030/244/329 for SUMO-2 isopeptide are defined
by y27, y18, y16, and y13 in A and b12, b21, b23, and b26 in B.
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tute the signature pattern (Fig. 3B). The complementary y ions
could still be detected albeit at lower intensity, e.g. y44 and y36
at m/z 4900.4 and 4044.3, respectively, which can be further
used as supporting evidence for confident sequence mapping.
Interestingly, we noted that if the SUMO-2-sumoylated tryptic
peptide from the substrate protein is itself terminating with an
Arg residue instead of Lys, the presence of Arg at both the C
and N termini of the isopeptide would lead to both y and b ion
series as exemplified by the SUMO-2-sumoylated S-tag isopep-
tides (supplemental Fig. S1). In this case, the isopeptide, which
did not carry the extra FR residues, afforded the expected y ion
series dominated by y17, y20, and y22 (supplemental Fig. S1A).
In contrast, the isopeptide with additional N-terminal FR res-
idues due to missed cleavage afforded strong b4, b12, b21, and
b23 ion signals, as well as y17, y20, y22, y31, and y39 ions (Fig.
S1B), due to the Arg residue at the C terminus of the sumoy-
lated tryptic peptide, ETAAAKFER.
Sumoylation of Ubc9 at the Non-consensus Site—Identifica-
tion of peptides matching to both SUMO-2 and Ubc9 from band
3 (Fig. 2) implicated a covalent complex of the two proteins.
Two putative isopeptides were detected by MALDI-TOF/TOF
MS analysis at high mass range, with their monoisotopic
[MH] molecular ion signals accurately mass-measured at
m/z 4110.9 and 4414.0, respectively, corresponding to a FR
residual mass difference. Both isopeptides were subjected to
MS/MS sequence mapping and the resulting y and b ions de-
tected (Fig. 4) confirm their identities, localizing the Lys
sumoylation site to the C-terminal peptide of Ubc9,
_AQAKKFAPS-COOH, similar to analogous position reported
for yeast Ubc9 (_AKQYSK-COOH) conjugation with Smt3p (9).
The putative isopeptide carrying the catalytic Cys93 of Ubc9
with thiol ester bond to SUMO-2 was not detected. This may
reflect that such isopeptide is transient and unstable whereby
the conjugated SUMO protein will be rapidly transferred to
substrate proteins. In the absence of other substrate proteins in
the in vitro system, Ubc9 may itself act as an acceptor, utilizing
a non-consensus site near its C terminus. It is reasonable to
assume that SUMO-1 can likewise sumoylate Ubc9, probably
at the same site, to yield the protein band 2 in Fig. 2. Indeed,
a candidate SUMO-1/Ubc9 isopeptide was barely detectable by
MALDI-MS analysis of its tryptic digestion products, further
MS/MS analysis of which yielded a series of y ions consistent
with the expected isopeptide sequence (data not shown). How-
ever, since the isopeptide molecular ion signal was very weak
and that the MALDI-TOF/TOF system employed could not
allow high resolution precursor isolation, the fragment ions
contribution from nearby precursors prevented an unambigu-
ous assignment. The data nevertheless indicated that the same
site on Ubc9 could be sumoylated in vitro by either SUMO-1 or
SUMO-2 depending on availability of the SUMO proteins, a
conclusion further echoed by our results on C28/C10 from
CENP-C (see later under “Results”).
SUMO-2 and SUMO-1 Sumoylation of C28 at the Consensus
Site—SDS-PAGE analysis revealed that the purified C28-His
gave an intense major band at about 45 kDa (Fig. 5, lane 5),
slightly below the creatine kinase band (46 kDa). Several ad-
ditional major bands could be detected when the C28 sample
was subjected to in vitro sumoylation with either SUMO-1
(lane 2) or SUMO-2 (lane 4). At first glance, several bands of 31
and 34 kDa (Fig. 5, bands 3–14) were commonly found irrespec-
tive of whether E1 was added to the reaction mixtures. LC-
MS/MS analyses (Table I), however, revealed that in the ab-
sence of E1 when the sumoylation reaction could not proceed
(lanes 1 and 3), only C28 could be identified from these protein
bands (bands 3–5 and 9–11), which probably represent the
various degraded forms of C28. When E1 was added, sumoyla-
tion could occur and resulted in additional identification of
Ubc9 and the SUMO proteins in bands 6 and 7 and 12 and 13.
These barely separated doublets may thus contain sumoylated
Ubc9 in addition to C28. It is also clear that band 14 appeared
to be broader than other bands (bands 5, 8, and 11) and was
found to also contain SUMO-2 proteins. Subsequent MALDI
MS/MS analysis led to detection of the implicated SUMO-2
conjugated SUMO-2 isopeptide (data not shown). These find-
ings are therefore consistent with those described above (Fig. 2)
when no C28 was added, and none of the 31/34-kDa bands
afforded any candidate isopeptide suggestive of sumoylated
C28 when screened by MALDI-MS and -MS/MS. Of interest
TABLE I
LC-MS/MS identification of protein bands from SDS-PAGE analysis
of the in vitro sumoylated C28 (Fig. 5)
Band
Protein identified (number of matched peptides /mascot
score)a
C28
(CENP-C) SUMO-1 SUMO-2 Ubc9
1 5/243 — 2/119 —
2 2/172 4/35 — —
3 8/305 — — —
4 8/308 — — —
5 9/491 — — —
6 8/340 4/132 — 6/201
7 8/348 2/56 — 8/246
8 10/466 — — —
9 7/338 — — —
10 10/412 — — —
11 8/469 — — —
12 9/395 — 3/93 6/173
13 8/336 — 3/104 7/261
14 10/444 — 3/124 —
a Proteins were identified by standard LC-MS/MS analyses of the
tryptic digestion products. MS/MS data were processed into peak lists
and searched against Swiss-Prot database using the Mascot program.
CENP-C was identified as top hit in all bands. Other non-relevant but
significant hits attributable to contaminants from the reaction mixtures
were not listed. “—” denotes not identified from the respective analysis.
FIG. 5. SDS-PAGE analysis of in vitro sumoylated C28 prod-
ucts with either SUMO-1GG or SUMO-2GG. The sumoylation reac-
tions contain C28-His, either SUMO-1GG or SUMO-2GG, E2 (Ubc9)
enzyme with and without E1 enzyme. Bands 1 and 2 are the C28-
sumoylated by SUMO-2GG and SUMO-1GG, respectively. Bands 3–14
correspond to partially degraded fragments of C28, as well as sumoy-
lated SUMO-2 (band 14), sumoylated Ubc9 (bands 6, 7, 12, and 13).
Results from LC-MS/MS identification of the protein bands are tabu-
lated in Table I.
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then are the two bands at 66 kDa that were also clearly
absent from the reaction mixtures if E1 was omitted.
In addition to peptides from C28, SUMO-2 and SUMO-1
peptides were found in the tryptic digests from bands 1 and 2,
respectively (Table I), which suggested that these two bands
correspond to sumoylated C28. For band 1, MALDI-TOF/TOF
MS analysis led to identification of a weak molecular ion signal,
the more abundant precursor signal of which was detected at
m/z 6146.8, corresponding exactly to the expected tryptic pep-
tide fragment of C28, 526RPSDWWVVKSEESPVYSNSSVR547,
conjugated with the SUMO-2 C-terminal peptide. The base
peak at m/z 456.2 in its MS/MS spectrum (Fig. 6A) could be
assigned as the b4 ion of the C28 tryptic peptide due to facile
cleavage at Asp529 and charge retention on the N-terminal
Arg526. Sequence mapping and localization of the sumoylation
site to Lys534 of the KXE consensus motif were afforded by a
series of prominent y ions (Fig. 6A). Importantly, all the b ions
related to the C28 tryptic peptides and the y ion series up to the
C-terminal GG of SUMO-2 (y23 and y24) were reproduced in the
MS/MS spectrum of a putative SUMO-1 sumoylated C28
FIG. 6. MALDI MS/MS spectra of the SUMO-2-conjugated C28 isopeptide (A) and SUMO-1-conjugated C28 isopeptide (B). The
spectrum in B is normalized to the intensity of the b12 ion signal, but only the portion below 50% intensity is shown. The detected y ion series in
A are analogous to those of SUMO-2 conjugated SUMO-2 isopeptides (Fig. 2) with the characteristic mass intervals of 1014/244/329 for SUMO-2
isopeptide being defined by y44, y35, y33, and y30. The same series of y6, y9–13, and y22–24 ions afforded by both SUMO-1 and SUMO-2 isopeptides
unambiguously defined the same tryptic peptide from C28 of CENP-C, sumoylated at Lys534 of the consensus site.
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isopeptide from band 2 (Fig. 6B). The accurate mass measure-
ment of the monoisotopic [MH] molecular ion signal at m/z
4730.2 and other detectable y ions, especially the intense y33
ion, confirmed that the same C28 tryptic peptide (aa 526–547)
could be sumoylated by SUMO-1 at the same Lys534 site, giving
rise to the analyzed isopeptide. Thus, protein bands 1 and 2
(Fig. 5) were confirmed to be SUMO-2- and SUMO-1-sumoy-
lated C28 of CENP-C, respectively.
SUMO-2 and SUMO-1 Sumoylation of C10 at Non-consensus
Sites—In the case of C10-His, no consensus sumoylation site
could be located, but SDS-PAGE analysis of the in vitro sumoy-
lation products suggested that C10 was sumoylated by
SUMO-2 and SUMO-1, yielding the protein bands 1 and 2,
respectively (Fig. 7). MALDI-MS analysis failed to detect any
molecular ion signals that may correspond to the predicted
isopeptide comprising the weakly potential sumoylation site
697GKND700. To search for other putative sumoylated isopep-
tides, MS/MS analyses were performed on all reasonably
strong signals at above m/z 4000. Four putative isopeptides
with the characteristic MS/MS signature pattern established
for SUMO-2 isopeptide were identified, two of which corre-
spond to SUMO-2-conjugated SUMO-2 isopeptides with and
without Met oxidation, affording a pair of monoisotopic
[MH] signals at m/z 5160.3 and 5176.3, respectively. The
other two signals, which gave monoisotopic [MH] at m/z
4292.0 and 4670.0, could be assigned as corresponding to
SUMO-2-conjugated tryptic peptides of C10, 718VIPKNR723,
and 745LKPLEYWR752, respectively, from MS/MS analyses
(Fig. 8, A and B). The mass intervals of 1030/244/329 could be
clearly attributed to the dominant y ions detected along with
neutral loss of 64 mass units consistent with the presence of an
oxidized Met.
As in the case of Ubc9 sumoylation, assuming that the same
sites that were sumoylated by SUMO-2 might likewise be
sumoylated by SUMO-1, the predicted SUMO-1/C10 isopep-
tides were indeed detected by MALDI-MS analysis of the tryp-
tic digests from band 2 (Fig. 7) at m/z 2878.4 and 3256.6
(monoisotopic masses). MS/MS analyses further confirmed the
sequence assignment as shown in Fig. 8, C and D. Thus, the
two non-consensus sites, Lys721 and Lys746, as in the C10
fragment of CENP-C, could be sumoylated in vitro by both
SUMO-1 and SUMO-2. Under the experimental conditions em-
ployed, each C10 fragment molecule was apparently sumoy-
lated at only one of the two sites and not both, since only one
major band could be detected. Since C10 is an artificially cre-
ated small polypeptide, it is not known whether the sumoyla-
tion detected may bear any in vivo significance, but our find-
ings shed light on the utilization of consensus versus non-
consensus sites in the substrate proteins. It is of interest to
note that of all the seven Lys residues in C10, the two identified
as sumoylation sites both correspond to Lys with adjacent Pro
residue. In contrast, the weakly potential site 697GKND700
could not be detected as sumoylated, but the corresponding
tryptic peptide terminating with an unmodified Lys698 could,
thus arguing that the in vitro sumoylation reaction was not a
random event targeting any Lys residue.
DISCUSSION
We have demonstrated in this work that tandem mass spec-
trometry is a powerful and effective analytical means to detect
and unequivocally map the sumoylation sites. Based on MS/MS
characteristics of SUMO-2-conjugated isopeptides, a concerted
strategy could be formulated to rapidly screen for SUMO-2-
conjugated isopeptides among the tryptic digestion products.
The excised band on SDS-PAGE would first be tryptic digested
followed by LC-MS/MS analysis for protein identification. The
particular band of interest should be found to contain peptide
matches from both the SUMO and substrate proteins. The use
of trypsin not only preserves the useful localization of Arg/Lys
to C termini for facile peptide MS/MS sequencing but should in
principle also cleave all non-sumoylated Lys sites. By defini-
tion, the isopeptide should have a minimum molecular mass
corresponding to the tryptic C-terminal peptide of SUMO-2 at
3567.5 or 3870.7 Da (monoisotopic mass) depending on whether
a missed cleavage at Arg61 is included, taking also into consid-
eration that the Met contained within may be oxidized to give
additional 16-mass unit increment. Rapid second tier
MALDI-MS mapping will be followed by acquisition of MS/MS
spectra for all detectable signals at above m/z 3600 on a
MALDI-TOF/TOF instrument, which allows for high sensitiv-
ity CID-MS/MS of precursor ions of high m/z values. If the
desirable characteristic patterns were detected, possible re-
lated isopeptide signals are sought at 16 mass units for Met
oxidation and 303 mass units for Phe-Arg residual mass
increment. Detection of SUMO-1-conjugated isopeptide is more
problematic as it lacks the critical Asp residues to induce the
dominant fragmentation pattern. However, our work demon-
strated that, at least for the in vitro system, sites that can be
sumoylated by SUMO-2 will also likely to be sumoylated by
SUMO-1. This may form the basis for identifying SUMO-1-
conjugated non-consensus sites.
Using this strategy, we have been able to not only detect the
sumoylated isopeptides from the protein bands on SDS-PAGE
but also provide additional MS/MS sequence mapping evidence
for the identified sumoylation site, especially if it does not
contain a consensus sequence motif (Table II). To our knowl-
edge, this is the first report on direct MS/MS sequencing of
sumoylated isopeptides. Distinctive features were identified
that can be used to rapidly screen for SUMO-2/3-conjugated
isopeptides within a complex digestion mixtures, as in shotgun
proteomics. In principle, computer scripts can be written to
automate real-time data-dependent MS/MS acquisition based
on the characteristic mass intervals. A 329/244/1014 increment
implies y ions for SUMO-2/3 C-terminal tryptic peptide without
missed cleavage, whereas the reverse order, i.e. 1014/329/244
increment, defines the b ion series and indicates the presence of
additional Phe-Arg residues at the N terminus. The molecular
weight of the tryptic peptide fragment from the substrate pro-
tein can subsequently be computed and matched against the
FIG. 7. SDS-PAGE analysis of in vitro sumoylated C10 prod-
ucts by either SUMO-1GG or SUMO-2GG. The sumoylation reac-
tions contain C10-His, SUMO-1GG or SUMO-2GG, E2 (Ubc9) enzyme
with and without E1 enzyme. Bands 1 and 2 are the C10 sumoylated by
SUMO-2GG and SUMO-1GG, respectively.
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known protein sequence, applying constraints for the presence
of a non-terminal Lys, probable but not necessary within a
KXE motif. In cases when the MS/MS data are of sufficiently
good quality, further confirmation of the sequence can be ob-
tained through additional y ions detected.
This investigation therefore establishes the ground work for
future SUMO proteomics studies. Only when more sumoyla-
tion sites could be definitively confirmed can bioinformatics
studies be meaningful to derive the actual consensus sumoyla-
tion site, taking into account its secondary and tertiary struc-
tures. Although the list of sumoylated sites continues to grow
steadily, the vast majority were mapped only by mutagenesis of
the putative acceptor lysines to arginines followed by analysis
of loss of modifications and/or sumoylation-implicated func-
tions. Such an experimental approach is, however, non-dis-
criminative against lack of acceptor site or impairment of
sumoylation enzyme-substrate interactions in the mutants.
KXE is apparently not sufficient nor absolutely necessary to
ensure sumoylation (2, 3). In the case of RanGAP1, crystallo-
graphic analysis showed that the acceptor Lys is part of an
accessible loop structure and reaches directly into the catalytic
cleft of Ubc9 (5). It has also been noted that most sumoylated
sequences contain Pro and/or Gly 2–5 aa upstream or down-
stream of the acceptor Lys, probably to help insuring the ac-
cessibility by introducing a turn. Alternatively, the sequence
motif is located near the very N- or C-terminal ends, which
could therefore be readily accessible (3). The two non-consensus
TABLE II
Sumoylation sites identified in this study by MALDI-TOF/TOF
MS/MS sequence mapping
Both SUMO-1- and SUMO-2-sumoylated isopeptides for all the im-
plicated sites could be detected and verified by MS/MS analyses except
for S-tag in which the candidate SUMO-1-sumoylated isopeptide has
not been actively sought.
Protein Site Flanking sequence of the identifiedsumoylation site
SUMO-2 Lys11 H2N-MADEKPKEGVKTENNDHINLK
Ubc9 Lys153 EYEKRVRAQAKKFAPS-COOH
S-tag Lys11 GSGMKETAAAKFERQHMDSPD
C28 Lys534 SRRPSDWWVVKSEESPVYSNS
C10 Lys721 DDSKQSKVIPKNRIHHKLVLP
Lys746 NVRRTKRTRLKPLEYWRGERI
FIG. 8. MALDI-MS/MS spectra of the C10 isopeptides sumoylated by SUMO-2 at Lys721 (A) and Lys746 (B) or SUMO-1 at Lys721 (C)
and Lys746 (D). The detected y ion series in A and B are analogous to those of SUMO-2-conjugated SUMO-2 isopeptides (Fig. 2) with the
characteristic mass intervals of 1030/244/329 for SUMO-2 isopeptide being defined by y28, y19, y17, and y14 in A and y30, y21, y19 and y16 in B. The
same series of y6–10 ions in A and C afforded by both SUMO-2 and SUMO-1 isopeptides unambiguously define the same tryptic peptide
718VIPKNR723 from C10 of CENP-C, sumoylated at Lys721; whereas the same y6, y8, y9, and y10 ions in B and D define the same tryptic peptide
745LKPLEYWR752 from C10 of CENP-C, sumoylated by either SUMO-2 or SUMO-1 at Lys746.
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sumoylation sites on the C10 fragment of CENP-C identified in
this study conform to the first scenario, namely with adjacent
proline. The sumoylation site on Ubc9 appears to conform to
the second scenario by virtue of its near C-terminal location.
Yet, many other reported cases in the literature do not follow
these simplistic rules and the issue of substrate specificity is
far from resolved, especially in real physiological context, in the
presence of other interacting and regulating factors including
E3 ligases.
The in vitro system coupled with MS analysis could in fact
serve as an assay system to screen for the identity and func-
tional effect of putative E3 ligases, as well as isopeptidases, on
the relative efficiency and specificity of sumoylation by
SUMO-1 and SUMO-2/3 families. Interestingly, we could fur-
ther detect isopeptide corresponding to SUMO-2 protein being
sumoylated by SUMO-1 at consensus site Lys11 in an in vitro
sumoylation system where both SUMO-1 and SUMO-2 pro-
teins were added (supplemental Fig. S2).2 While polymeriza-
tion of SUMO-2 has been reported (8, 9), it is unclear whether
SUMO-1 may also be added on a growing chain of SUMO-2 to
cap the reactions. This finding, coupled with our observation
that most identified sites could be equally sumoylated by both
SUMO-1 and SUMO-2, suggest a regulatory mechanism that
may be more complicated than anticipated thus far.
Relying on the SDS-PAGE to resolve potentially multi-
sumoylated products, we could identify only a major band each
for the sumoylated C28 and C10 fragments. In the case of C28,
which contains a consensus KXE sumoylation site, the only
isopeptide identified was that expected, suggesting that C28
was mainly monosumoylated at the consensus site despite the
presence of another Lys in C28 that is followed by Pro. In
contrast, for the C10 fragment, which carries no apparent
perfect consensus sumoylation site, the single major band de-
tected was interpreted as corresponding to co-migrating C10
fragments monosumoylated at either of the two non-consensus
sites identified. This conclusion is based primarily on positive
identification of both isopeptides and the corresponding tryptic
peptides spanning an unmodified Lys. Thus a weakly potential
site such as GKND was found to be less preferred than Lys
preceded or followed by Pro, which in turn indicates that a
certain selectivity was maintained. It should be pointed out
that our analytical strategy relies on tryptic cleavage, which
would potentially cleave at all non-modified Lys, but not all
resulting in-gel-digested tryptic peptides could be detected,
especially those comprising only a few amino acids. It is there-
fore not possible to categorically rule out a sumoylation based
on detecting the unmodified tryptic peptide. A major technical
advance suggested by the current work is the successful appli-
cation of MALDI-TOF/TOF MS/MS to identify instead the im-
plicated isopeptides at the high mass end. When combined with
size fractionation on SDS-PAGE, barring any abnormality in
electrophoretic mobility, the approach should adequately es-
tablish the sumoylation pattern and the preferred site selec-
tion, as demonstrated here for the CENP-C fragments.
It remains to be established whether the identified CENP-C
sumoylation sites are likewise sumoylatd in vivo. Identification
of SUMO-1 as a suppressor of CENP-C mutants provided a first
possible connection between CENP-C function and sumoyla-
tion (15). CENP-C and centromere were further associated, in
a cell cycle-regulated manner, with nuclear dots ND10 proteins
(PML, SP100, Daxx etc.) modified by SUMO-1 (28–30).
Whether CENP-C itself is reversibly sumoylated by SUMO-1 or
SUMO-2/3, or both, at a particular state of chromosome dynam-
ics has been difficult to demonstrate via conventional ap-
proaches. The advent of MS and proteomics has been used
successfully to define the yeast kinetochore protein complex
and the centromere complex from HeLa interphase cells (31,
32). These analyses can now be further coupled with definitive
identification of sumoylation sites among the principal compo-
nents in conjunction with reconstituted in vitro sumoylation
system to delineate a highly complicated and dynamic cellular
process.
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Fig. S1. MALDI MS/MS spectra of the SUMO-2 conjugated S-tag isopeptide (A) and that 
with additional N-terminal FR due to trypsin missed cleavage at Arg61 (B). The S-Tag 
(GSGMKETAAAKFERQHMDSDDLGTGGGSGIEGR) is commonly inserted at the N-termini 
of various proteins. The consensus sumoylation site present in S-Tag was found unexpectedly to 
be sumoylated by SUMO-2. This tag is therefore not suitable for insertion into substrate proteins 
or the SUMO proteins for sumoylation studies. 
Fig. S2. MALDI MS/MS spectra of the SUMO-1 conjugated SUMO-2 isopeptide. A protein
band containing both SUMO-1 and SUMO-2 peptides was identified by LC-MS/MS analysis of 
the in vitro sumoylation reaction products when both SUMO-1 and SUMO-2 were added. The 
predicted SUMO-2/SUMO-1 isopeptide with monoisotopic [M+H]+ molecular ion at m/z 3762.7 
was then isolated for MALDI MS/MS analysis despite its low intensity in the MALDI mass 
spectrum. Not all fragment ions originated from the isopeptide as other neighboring precursors 
were also co-selected. The y series of fragment ions detected were however of sufficient quality 
to unambiguously confirm the identity of the implicated isopeptide, localizing the SUMO-1 
conjugated site of SUMO-2  at the expected Lys11.
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